Asymmetrical Dimethylarginine (ADMA) Antibody
299€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Asymmetrical Dimethylarginine (ADMA) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx102968
tested applications
ELISA
Description
Polyclonal Antibody to Asymmetrical Dimethylarginine (ADMA).
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Target: Asymmetrical Dimethylarginine (ADMA) Immunogen: abx165649 - ADMA conjugated to BSA |
| Host | Rabbit |
| Reactivity | General |
| Recommended Dilution | IHC (Predicted): 5-20 µg/ml, IF/ICC (Predicted): 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Purification | Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography. |
| Size 1 | 100 µl |
| Size 2 | 200 µl |
| Size 3 | 1 ml |
| Form | Liquid |
| Tested Applications | ELISA |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-7 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | ADMA |
| Background | Antibody anti-ADMA |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Descripción
Asymmetrical dimethylarginine (ADMA) is an endogenous molecule that competitively inhibits nitric oxide synthase (NOS), thereby reducing nitric oxide (NO) production and impairing vascular tone, endothelial function, and blood flow. As a key regulator of NO bioavailability, ADMA is a critical factor in cardiovascular health. Elevated ADMA levels are associated with endothelial dysfunction, hypertension, atherosclerosis, and heart failure, as insufficient NO contributes to inflammation, vascular rigidity, and oxidative stress. ADMA is metabolized by dimethylarginine dimethylaminohydrolase (DDAH), and any imbalance between ADMA production and clearance affects vascular and metabolic health. Beyond cardiovascular diseases, ADMA dysregulation is linked to chronic kidney disease, diabetes, and neurodegenerative disorders. ADMA serves as a biomarker for assessing cardiovascular and metabolic risks, and targeting the DDAH-ADMA-NO pathway is an emerging strategy to restore endothelial health and reduce vascular inflammation.
Related Products
Asymmetric Dimethylarginine (BSA)
Asymmetric Dimethylarginine (BSA) is a small molecule conjugated to Bovine Serum Albumin (BSA).
Ver Producto